Dana-Farber Cancer Institute Inc 2025 Other Report
The report follows Dana-Farber's research pathway from foundational science to the FDA approval of belzutifan for kidney cancer, while also exploring personalized NeoVax cancer vaccines. It highlights the Centers for Early Detection and Interception, which bring clinical care and research together to identify and prevent cancer earlier. The Pan-Mass Challenge generated a record-breaking $75 million in 2024 and pushed lifetime fundraising for Dana-Farber to $1.047 billion.
Company: Dana-Farber Cancer Institute Inc
Sector: Healthcare & social services
Country: United States
Year: 2025
Type: Other Report
Pages: 52
Back to company
Dana-Farber Cancer Institute Inc
Paths Of Progress
The report follows Dana-Farber's research pathway from foundational science to the FDA approval of belzutifan for kidney cancer, while also exploring personalized NeoVax cancer vaccines. It highlights the Centers for Early Detection and Interception, which bring clinical care and research together to identify and prevent cancer earlier. The Pan-Mass Challenge generated a record-breaking $75 million in 2024 and pushed lifetime fundraising for Dana-Farber to $1.047 billion.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Oct 1, 2023 - Sep 30, 2024
Fiscal Year
2024
Type
Other Report
Language
English
Pages
File Size
Standards & Assurance
No data available
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available